Hyperkalaemia ECG progression is a predictable, highly ordered sequence of electrocardiographic alterations reflecting the progressive electrophysiological toxicity of elevated extracellular potassium (K^+) concentrations on myocardial tissue ^1,2. As serum potassium levels rise above normal physiological bounds (~3.5–5.0 mEq/L), the transmembrane electrical gradient across cardiac myocytes is altered, slowing myocardial conduction velocity, depressing automaticity, and inducing life-threatening re-entrant or bradyarrhythmic events ¹. Because the clinical correlation between serum potassium levels and absolute cardiac toxicity can occasionally be variable, recognizing the precise architectural stages of ECG progression remains the gold standard for guiding emergency intervention before irreversible ventricular arrest occurs ³.

Etiology & Risk Factors

• Impaired Renal Excretion: The predominant cause of chronic and acute hyperkalaemia, driven by advanced chronic kidney disease (CKD), acute kidney injury (AKI), severe oliguria or anuria, and hypoaldosteronism (e.g., type 4 renal tubular acidosis, diabetic nephropathy) ^1,2.
• Medication-Induced Impairment: Frequent pharmacological triggers include renin-angiotensin-aldosterone system (RAAS) inhibitors (ACE inhibitors, ARBs, direct renin inhibitors), mineralocorticoid receptor antagonists (spironolactone, eplerenone), potassium-sparing diuretics (amiloride, triamterene), non-steroidal anti-inflammatory drugs (NSAIDs), beta-blockers, and calcineurin inhibitors ¹.
• Transcellular Shifts: Extracellular potassium loading resulting from acute metabolic acidosis (where extracellular hydrogen ions shift into cells in exchange for intracellular potassium), severe rhabdomyolysis, tumor lysis syndrome, massive hemolysis, severe digitalis toxicity, and strenuous physical exertion ^1,2.
• Exogenous Overload: Aggressive intravenous or oral potassium chloride supplementation, massive blood transfusions containing stored aged erythrocytes, and ingestion of potassium salt substitutes ¹.
• Pseudohyperkalaemia: Spurious laboratory elevation caused by in vitro hemolysis during difficult venipuncture, prolonged tourniquet application, aggressive fist clenching, extreme leukocytosis ($WBC > 50,000/\mu L$), or thrombocytosis ($platelets > 500,000/\mu L$) ².

Pathophysiology

Cardiac resting membrane potential is predominantly determined by the ratio of intracellular to extracellular potassium concentrations, maintained by the Na+/K+-ATPase pump and the high resting permeability of inward rectifier potassium channels ($I_{K1}$). According to the Nernst equation, an elevation in extracellular potassium ($[K^+]_o$) decreases the concentration gradient across the sarcolemma, causing partial depolarization of the resting membrane potential from its normal baseline of approximately -90 mV toward a less negative threshold potential (e.g., -70 mV) ^1,2. Initially, this mild depolarization enhances cell excitability. However, as extracellular potassium continues to climb, the sustained resting depolarization inactivates voltage-gated fast sodium ($Na_V1.5$) channels in a voltage-dependent manner. The inactivation of these channels dramatically reduces the upstroke velocity ($\text{d}V/\text{d}t_{\max}$) of Phase 0 of the cardiac action potential, slowing action potential propagation through specialized conduction networks (the sinoatrial node, atrioventricular node, bundle of His, and Purkinje fibers) ^1,3. Concurrently, outward repolarizing potassium currents (such as the transient outward current $I_{to}$ and rapid delayed rectifier current $I_{Kr}$) are enhanced and accelerated, shortening action potential duration and creating the hallmark narrow, tented T waves. As toxicity advances, profound intraventricular conduction block occurs, culminating in the loss of coordinated mechanical contraction and the genesis of pre-terminal sine-wave rhythms ^2,3.

Clinical Presentation & Classic Clinical Signs

• History & Cardinal Symptoms: Patients frequently present with vague constitutional and neuromuscular complaints, including progressive generalized muscle weakness, heavy limbs, ascending neuromuscular paralysis resembling Guillain-Barré syndrome, paresthesias, nausea, palpitations, lightheadedness, or sudden syncope ^1,2. In severe cases, rapid cardiovascular collapse or pulseless electrical activity (PEA) arrest may be the initial presentation ³.
• Physical Examination & Named Clinical Signs: Examination may reveal flaccid muscle weakness with depressed or absent deep tendon reflexes, bradycardia, hypotension, peripheral edema related to underlying renal failure, and signs of extracellular volume overload ^1,2. Sensation is typically preserved despite profound motor weakness.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Staging, Classification & Clinical Scoring Systems

Differential Diagnosis

Management & Treatment Protocol

• Initial Stabilization & Resuscitation: Immediate deployment of continuous cardiac telemetry and acquisition of an emergency 12-lead ECG. If any ECG abnormalities (peaked T waves, PR/QRS prolongation) or severe serum elevation ($\ge 6.5\text{ mEq/L}$) are present, administer membrane stabilization instantly ^1,3.
• First-Line Medical / Pharmacological Therapy (with exact adult dosing):
  • Membrane Stabilization: Administer Intravenous Calcium Gluconate (10%, 10–30 mL over 2–5 minutes) or Calcium Chloride (10%, 5–10 mL via central line over 2–5 minutes) to antagonize membrane effects without altering serum potassium ^1,2. Repeat ECG in 5 minutes; if changes persist, repeat dose once.
  • Intracellular Shifting: Administer regular human insulin (10 units IV bolus) concurrently with 50 mL of 50% Dextrose (D50W) intravenously over 5 minutes to prevent hypoglycaemia, acting within 15–30 minutes. In non-urgent settings or as an adjunct, administer nebulized Albuterol (10–20 mg in 4 mL normal saline over 10 minutes) ^1,3.
  • Systemic Alkalinization: Sodium bicarbonate (50–150 mEq in 1 L D5W infused over 2–4 hours) is reserved for patients with concurrent severe metabolic acidosis ($\text{pH} < 7.20$) or advanced renal failure ¹.
• Potassium Removal & Elimination:
  • Gastrointestinal Cation Binders: Sodium zirconium cyclosilicate (SZC; 10 g orally three times daily for up to 48 hours) or patiromer (8.4 g to 25.2 g orally once daily) for subacute or outpatient reduction ¹.
  • Renal Excretion: Loop diuretics (e.g., furosemide 40–80 mg IV) combined with isotonic saline hydration if the patient is volume depleted and renal function permits ¹.
  • Renal Replacement Therapy: Emergency hemodialysis is the definitive gold-standard treatment for patients with end-stage renal disease, refractory severe hyperkalaemia, or life-threatening arrhythmias unresponsive to medical management ^1,3.
• Surgical / Interventional Indications: Urgent vascular access placement (dual-lumen dialysis catheter) for emergent haemodialysis or continuous renal replacement therapy (CRRT) in treatment-refractory cases ¹.

Complications & Prognosis

• Major Electrophysiological Complications: Progression to idioventricular escape rhythms, high-grade atrioventricular block, slow atrial fibrillation, sine-wave transformation, ventricular tachycardia, ventricular fibrillation, pulseless electrical activity (PEA), and sudden cardiac death ^1,3.
• Neuromuscular Morbidity: Severe ascending flaccid paralysis, respiratory muscle weakness requiring mechanical ventilatory support, and prolonged post-resuscitation intensive care stays ^1,2.
• Prognosis: Highly favorable when recognized promptly via routine ECG screening and managed aggressively with membrane stabilization and elimination protocols. Unrecognized or delayed intervention carries an exceptionally high mortality rate due to sudden, catastrophic malignant arrhythmias ^2,3.